ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.

Biotechnology

ARTBIO

ARTBIO's headquarters in Cambridge, United States

Emanuele Ostuni

Nick Pullen

Calvin J. Lee

Margaret Yu

Victor Paulus

Philippe Dasse

The Leadership Team at ARTBIO is responsible for steering the company’s strategic vision and operational execution. This team, comprised of key executives including the CEO, Vice Presidents, and Heads of various critical departments, ensures the integration of clinical development, scientific research, regulatory affairs, quality management, and supply chain processes to advance ARTBIO's pioneering alpha radioligand therapies. Their collaborative efforts drive decision-making and align the company's activities with its patient-centric mission and goals.

Leadership Team

The Product Development and Quality Assurance team at ARTBIO is responsible for overseeing the design, development, and manufacturing processes of alpha radioligand therapies. They ensure the therapies meet high-quality standards and regulatory requirements. This team collaborates closely with other departments to guarantee the safe, effective, and efficient delivery of therapies to patients.

ARTBIO

Org chart

Teams

Leadership Team

Product Development and Quality Assurance

Offices

ARTBIO

Org chart

Teams

Leadership Team

Product Development and Quality Assurance

Offices

Related companies